SynthesisFrontiers in pharmacology2025
Efficacy and safety of Tongxinluo in the treatment of stroke: a systematic review and meta-analysis of randomized controlled trials.
Synthesis in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To evaluates the efficacy and safety of Tongxinluo in treating stroke. Methods: PubMed, Web of Science, Cochrane Library, Embase, China National Knowledge Infrastructure and Wanfang databases were performed to search literature from 2000 to 2024. Randomized controlled trials evaluating Tongxinluo for stroke were included. The primary outcomes were efficacy and safety. Sensitivity and subgroup analyses were conducted to assess result stability and identify sources of heterogeneity. All analyses were conducted using Review Manager 5.4 and STATA 15.1. Results: Fifty-one RCTs including 9,577 participants for analysis. Tongxinluo significantly outperformed the control group in efficacy [RR = 1.20, 95% CI (1.16, 1.25)]. Adverse event incidence between groups showed no significant difference [RR = 1.01, 95% CI (0.90, 1.12)]. Additionally, Tongxinluo significantly improved NIHSS, total cholesterol (TC), and serum hypersensitive C-reactive protein (hs-CRP) levels in stroke individuals. Conclusion: Tongxinluo, as an adjunctive treatment for stroke, offers superior clinical efficacy compared to conventional treatments without increasing adverse event risk. However, due to study limitations, further multicenter, large-sample RCTs are required to confirm. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.